title: Medication-based urolithiasis and atazanavir.
authors: Department of Medicine, Division of Infectious Diseases, University of Toronto, Toronto, Ont, Canada.
authors: Paul M
authors: PM
authors: Koblic
authors: Wayne L
authors: WL
authors: Gold
authors: Charles J L
authors: CJ
authors: la Porte
authors: Todd C
authors: TC
authors: Lee
mesh_terms: D044966:Anti-Retroviral Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000032:analysis; D000069446:Atazanavir Sulfate; D015224:Dideoxynucleosides / Q000008:administration & dosage / Q000009:adverse effects* / Q000032:analysis; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides / Q000627:therapeutic use; D011725:Pyridines / Q000627:therapeutic use; D019438:Ritonavir / Q000627:therapeutic use; D014527:Uric Acid / Q000097:blood; D014545:Urinary Calculi / Q000737:chemistry*; D052878:Urolithiasis / Q000139:chemically induced*; D000099227:Abacavir
chemical_list: D044966:Anti-Retroviral Agents; D000069446:Atazanavir Sulfate; D015224:Dideoxynucleosides; D019259:Lamivudine; D009842:Oligopeptides; D011725:Pyridines; D019438:Ritonavir; D014527:Uric Acid; D000099227:Abacavir